IDH1 and cholangiocarcinoma: Ivosidenib is an oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), and it was specifically approved by the FDA for adult patients with previously treated, locally advanced, or metastatic CCA with an IDH1 mutation [49].